By Chelsea Naso ( June 24, 2015, 4:34 PM EDT) -- Massachusetts-based Bluebird Bio Inc. raked in $500 million in a follow-on offering Tuesday, the day after the clinical-stage genetic and rare disease biotech inked a deal with Kite Pharma Inc. to together develop an immunotherapy treatment for cancers associated with human papillomavirus....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.